International Journal of Nephrology / 2018 / Article / Tab 3

Clinical Study

Prognostic Factors for Survival and Relapse in ANCA-Associated Vasculitis with Renal Involvement: A Clinical Long-Term Follow-Up Study

Table 3

Diagnostic, histological, and clinical factors to predict patient survival, renal survival, and relapse-free survival (N=82).

Univariate analysisMultivariate analysis
EndpointsPredictorsHR (95% CI)PHR (95% CI)P

Patient survivalDg MPA2.71 (1.37-5.35)0.004
ANCA MPO2.67 (1.37-5.19)0.0042.12 (1.08-4.17)0.03
Histopathological classFocal0.29 (0.12-0.69)0.005
Crescentic0.26 (0.10-0.67)0.006
Mixed0.69 (0.30-1.59)0.38
Female0.67 (0.34-1.32)0.25
Age ≥58 years8.50 (3.84-18.79)<0.0017.64 (3.44-16.95)<0.001
Proteinuria >3g/d0.94 (0.43-2.04)0.87
GFR <30ml/min/1.73m2.08 (1.07-4.04)0.03
Treatment with CYC0.42 (0.20-0.88)0.02

Renal survivalDg MPA2.71 (1.13-6.52)0.03
ANCA MPO3.17 (1.31-7.64)0.013.10 (1.21-7.95)0.02
Histopathological classFocal0.11 (0.03-0.41)0.001
Crescentic0.32 (0.11-0.90)0.03
Mixed0.49 (0.18-1.33)0.16
Female0.36 (0.14-0.96)0.040.26 (0.10-0.73)0.01
Age ≥58 years2.50 (1.10-5.71)0.03
Proteinuria >3g/day2.46 (1.08-5.60)0.03
GFR <30ml/min/1.735.63 (1.92-16.49)0.0024.10 (1.35-12.49)0.01
Treatment with CYC0.43 (0.18-1.04)0.06

Relapse freeDg MPA0.48 (0.28-0.82)0.010.48 (0.28-0.82)0.01
survivalANCA MPO0.59 (0.34-1.01)0.05
Histopathological classFocal1.29 (0.54-3.08)0.56
Crescentic1.82 (0.75-4.41)0.19
Mixed1.07 (0.40-2.82)0.90
Female1.19 (0.70-2.02)0.53
Age ≥58 years0.70 (0.41-1.20)0.20
Proteinuria >3g/d0.75 (0.38-1.49)0.42
GFR <30ml/min/1.73m0.59 (0.35-1.00)0.05
Treatment with CYC2.04 (0.92-4.52)0.08

Reference groups: ,GPA; , ANCA-PR3; , sclerotic; , male; , age <58 years; , Proteinuria ≤3g/day; , GFR ≥30ml/min; no CYC.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.